glp-1 multiple endocrine neoplasia receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Glucagon-Like Peptide-1 Based Therapies: A

muciniphila levels, which is arguably the population most in need of metabolic improvement

Orforglipron (Foundayo) is the first nonpeptide, oral, oncedaily GLP1 receptor agonist, marking a meaningful shift in GLP1 therapy

You're just not going to be able to achieve that, which is why I would say to everyone listening to this, if you suspect you have a thyroid condition, your best, best efforts now to get with a provider, get it diagnosed and start reversing that because Hashimoto's can be reversed, not cured, but the autoimmune attack can be reversed

So even if you dont have a gross deficiency of B12 throughout your life, you may feel the biochemical effects of subclinical B12 deficiency in energy production and how you feel